JP7308146B2 - インターロイキン１受容体関連キナーゼの阻害剤およびその使用 - Google Patents

インターロイキン１受容体関連キナーゼの阻害剤およびその使用 Download PDF

Info

Publication number
JP7308146B2
JP7308146B2 JP2019527449A JP2019527449A JP7308146B2 JP 7308146 B2 JP7308146 B2 JP 7308146B2 JP 2019527449 A JP2019527449 A JP 2019527449A JP 2019527449 A JP2019527449 A JP 2019527449A JP 7308146 B2 JP7308146 B2 JP 7308146B2
Authority
JP
Japan
Prior art keywords
optionally substituted
unsubstituted
substituted
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535759A (ja
JP2019535759A5 (OSRAM
Inventor
グレイ，ナタナエル，エス．
チャン，ティンフー
ハッチャー，ジョン
バーラージ，サラ，ジェーン
Original Assignee
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Publication of JP2019535759A publication Critical patent/JP2019535759A/ja
Publication of JP2019535759A5 publication Critical patent/JP2019535759A5/ja
Application granted granted Critical
Publication of JP7308146B2 publication Critical patent/JP7308146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2019527449A 2016-11-22 2017-11-22 インターロイキン１受容体関連キナーゼの阻害剤およびその使用 Active JP7308146B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425503P 2016-11-22 2016-11-22
US62/425,503 2016-11-22
PCT/US2017/063139 WO2018098367A1 (en) 2016-11-22 2017-11-22 Inhibitors of interleukin-1 receptor-associated kinases and uses thereof

Publications (3)

Publication Number Publication Date
JP2019535759A JP2019535759A (ja) 2019-12-12
JP2019535759A5 JP2019535759A5 (OSRAM) 2021-01-14
JP7308146B2 true JP7308146B2 (ja) 2023-07-13

Family

ID=60703094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527449A Active JP7308146B2 (ja) 2016-11-22 2017-11-22 インターロイキン１受容体関連キナーゼの阻害剤およびその使用

Country Status (6)

Country Link
US (1) US10975055B2 (OSRAM)
EP (1) EP3544970B1 (OSRAM)
JP (1) JP7308146B2 (OSRAM)
AU (1) AU2017363313B2 (OSRAM)
CA (1) CA3042731A1 (OSRAM)
WO (1) WO2018098367A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL322809A (en) 2017-09-22 2025-10-01 Kymera Therapeutics Inc Protein Decomposers and Their Uses
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020081572A1 (en) * 2018-10-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
AU2020386639A1 (en) * 2019-11-22 2022-06-02 Shangpharma Innovation Inc. Caspase 6 inhibitors and uses thereof
JP7390487B2 (ja) * 2019-12-03 2023-12-01 サムジン ファーマシューティカル カンパニー，リミテッド 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
PH12022552458A1 (en) 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
CN115484954A (zh) * 2020-03-23 2022-12-16 达纳-法伯癌症研究所股份有限公司 Irak1的有效和选择性不可逆抑制剂
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US20230295146A1 (en) * 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
MX2023007852A (es) 2020-12-30 2023-07-07 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4291187A4 (en) 2021-02-15 2025-01-15 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4308096A4 (en) * 2021-03-17 2025-04-16 Merck Sharp & Dohme LLC Heteroaroylamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
AU2023214044A1 (en) 2022-01-31 2024-08-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
JP2014533695A (ja) 2011-11-17 2014-12-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2015106058A1 (en) 2014-01-09 2015-07-16 Merck Patent Gmbh Pyrimidine pyrazolyl derivatives and their use as irak inhibitors
WO2016081679A1 (en) 2014-11-20 2016-05-26 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
EP3079682A4 (en) * 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015154038A1 (en) * 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533695A (ja) 2011-11-17 2014-12-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2015106058A1 (en) 2014-01-09 2015-07-16 Merck Patent Gmbh Pyrimidine pyrazolyl derivatives and their use as irak inhibitors
WO2016081679A1 (en) 2014-11-20 2016-05-26 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof

Also Published As

Publication number Publication date
CA3042731A1 (en) 2018-05-31
US20190276426A1 (en) 2019-09-12
WO2018098367A1 (en) 2018-05-31
JP2019535759A (ja) 2019-12-12
US10975055B2 (en) 2021-04-13
EP3544970B1 (en) 2021-11-17
AU2017363313B2 (en) 2021-06-24
US20200299257A9 (en) 2020-09-24
EP3544970A1 (en) 2019-10-02
AU2017363313A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP2021514958A (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
EP3341007B1 (en) Malt1 inhibitors and uses thereof
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US20220372017A1 (en) Hck degraders and uses thereof
JP7389749B2 (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
EP3814365B1 (en) Dot1l degrader and uses thereof
JP2018529649A (ja) フェニルスルホンアミド−ベンゾフラン誘導体およびその使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
AU2020301399B2 (en) HCK degraders and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230703

R150 Certificate of patent or registration of utility model

Ref document number: 7308146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150